Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer

被引：22
|
作者：
Moroni, M [1 ]
Sartore-Bianchi, A
Benvenuti, S
Artale, S
Bardelli, A
Siena, S
机构：
[1] Osped Niguarda Ca Granda, Falck Div Med Oncol, Milan, Italy
[2] Univ Turin, Inst Canc Res & Treatment, Oncogenom Ctr, Sch Med, I-10124 Turin, Italy
[3] IFOM, Inst Mol Oncol, FIRC, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷 / 11期
关键词：
targeted therapies; EGFR inhibitors; angiogenesis inhibitors; gastric cancer; esophageal cancer;
D O I：
10.1093/annonc/mdi356
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1848 / U5
页数：2
相关论文
共 50 条
  • [1] Activating mutation of the EGFR gene is rare and not responsible for gefitinib sensitivity in colorectal cancer
    Ogino, S
    Brahmandam, M
    Cantor, M
    Namgyal, C
    Kawasaki, T
    Loda, M
    Fuchs, CS
    [J]. LABORATORY INVESTIGATION, 2005, 85 : 114A - 114A
  • [2] EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer
    Sasaki, H
    Endo, K
    Mizuno, K
    Yano, M
    Fukai, I
    Yamakawa, Y
    Fujii, Y
    [J]. LUNG CANCER, 2006, 51 (01) : 135 - 136
  • [3] EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer
    Sasaki, Hidefumi
    Endo, Katsuhiko
    Haneda, Hiroshi
    Suzuki, Eriko
    Yukiue, Haruhiro
    Kobayashi, Yoshihiro
    Yano, Motoki
    Fujii, Yoshitaka
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [4] High EGFR somatic mutation frequency targeting the TK domain in colorectal cancer patients with microsatellite instability (MSI)
    Deihimi, Safoora
    Slifker, Michael
    Ross, Eric A.
    El-Deiry, Wafik S.
    [J]. CANCER RESEARCH, 2017, 77
  • [5] Activating mutation of the EGFR gene is rare and not responsible for gefitinib sensitivity in colorectal cancer expression
    Ogino, S
    Brahmandam, M
    Cantor, M
    Namgyal, C
    Kawasaki, T
    Loda, M
    Fuchs, CS
    [J]. MODERN PATHOLOGY, 2005, 18 : 114A - 114A
  • [6] EGFR mutation and response of lung cancer to gefitinib -: Reply
    Kobayashi, S
    Tenen, DG
    Halmos, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (20): : 2136 - 2136
  • [7] Chinese EGFR mutation characteristics and sensitivity to gefitinib in lung cancer patients
    Wu, Y
    Lin, J
    Wang, K
    Xu, C
    Zhou, Q
    Chen, G
    Yang, X
    Yang, J
    Liao, R
    Huang, Y
    [J]. LUNG CANCER, 2005, 49 : S114 - S114
  • [8] The somatic mutation landscape of Chinese Colorectal Cancer
    Ma, Rong
    Jing, Changwen
    Zhang, Yuan
    Cao, Haixia
    Liu, Siwen
    Wang, Zhuo
    Chen, Dan
    Zhang, Junying
    Wu, Yang
    Wu, Jianzhong
    Feng, Jifeng
    [J]. JOURNAL OF CANCER, 2020, 11 (05): : 1038 - 1046
  • [9] EGFR mutation in renal cell carcinoma confers sensitivity to gefitinib treatment
    Sokolenko, A.
    Iyevleva, A.
    Novik, A.
    Ivantsov, A.
    Moiseyenko, V.
    Imyanitov, E.
    [J]. EJC SUPPLEMENTS, 2008, 6 (09): : 107 - 107
  • [10] Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
    Mitsudomi, Tetsuya
    [J]. LANCET ONCOLOGY, 2011, 12 (08): : 710 - 711
12345